PT - JOURNAL ARTICLE AU - Raabe, Vanessa N. AU - Fleming, Andrew AU - Samanovic, Marie I. AU - Lai, Lilin AU - Belli, Hayley M. AU - Mulligan, Mark J. AU - Belmont, H. Michael TI - Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among health care workers at risk for SARS-CoV-2 exposure: A nonrandomized controlled trial AID - 10.1101/2022.07.01.22277058 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.01.22277058 4099 - http://medrxiv.org/content/early/2022/07/03/2022.07.01.22277058.short 4100 - http://medrxiv.org/content/early/2022/07/03/2022.07.01.22277058.full AB - Background Aerosol-generating procedures increase the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among health care workers (HCWs). An effective pre-exposure prophylaxis would mitigate this risk.Objective To determine the efficacy of pre-exposure prophylactic hydroxychloroquine for the prevention of SARS-CoV-2 infection and symptomatic coronavirus 19 disease (COVID-19) among HCWs at high occupational risk of SARS-CoV-2 exposure.Methods 130 HCWs in the New York University Langone Health System (NYULHS) who performed aerosol-generating procedures on patients with COVID-19 or provided bedside care for inpatients with COVID-19 or persons with suspected COVID-19 in an emergency department, for at least three shifts in a 7-day period, during the first 2020 COVID-19 wave in New York City were enrolled. Participants elected to take oral hydroxychloroquine, 600 mg on day 1 followed by 200 mg daily, or not take hydroxychloroquine for up to 90 days. Participants self-collected dried blood spots and completed digital questionnaires regarding COVID-19 symptoms, adverse events, and other COVID-19 medication use.Results Six participants (7.5%) seroconverted during the trial: four who took hydroxychloroquine (6.8%) and two who declined hydroxychloroquine (9.5%). All participants not taking hydroxychloroquine reported COVID-19 symptoms at seroconversion compared to one of four participants (25%) who took hydroxychloroquine. Adverse events occurred in eight participants (9.6%) on hydroxychloroquine and were mostly mild.Conclusions This study (ClinicalTrials.gov NCT04354870) did not demonstrate a statistically significant difference in SARS-CoV-2 seroconversion associated with hydroxychloroquine pre-exposure prophylaxis among HCWs at high risk of occupational SARS-CoV-2 exposure, although was underpowered and a high rate of hydroxychloroquine discontinuation was observed.Competing Interest StatementThe authors report the following potential conflicts of interest: MJM: Laboratory research and clinical trials contract funding for vaccines or monoclonal antibodies to SARS-CoV-2 with Lilly, Pfizer, and Sanofi Pasteur; personal fees for Scientific Advisory Board service from Merck & Co, Meissa Vaccines, Inc. and Pfizer. VNR: Clinical trials contract funding for vaccines to SARS-CoV-2 with Sanofi Pasteur and Pfizer. Laboratory research funding related to Ebola vaccine from Merck & Co.Clinical TrialNCT04354870Funding StatementThe New York University Langone Health System provided funding for this study. This study was conducted using clinical support provided the NYU-H+H Clinical and Translational Science Institute (CTSI), which is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001445.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the New York University Grossman School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual level data from participants will not be shared to protect the privacy of the participating health care workers.